The move is aimed at complimenting Mansfield, Mass.-based Covidien’s pulmonary portfolio, including its i-Logic lung navigation system.
The Viviasight SL device uses a small camera and ventilation tube to help surgeons with lung isolation during thoracic, cardiac, vascular or esophageal procedures, according to a press release.
Medical device company Holaira said it drummed up $10 million, changed its name and moved its headquarters.
Formerly known as Innovative Pulmonary Solutions, Holaira said it plans to use the Series C round to develop its minimally invasive devices to treat obstructive lung disease. All of Holaira’s existing backers participated, namely Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, and Versant Ventures.
Sanovas said it’s asked the FDA for 510(k) clearance for its Vas Zeppelin Smart Catheter, designed to diagnose and treat chronic pulmonary conditions and lung cancer.
The Sausalito, Calif.-based medical device company bills the device as "among the smallest interventional catheters," saying it’s designed to "overcome the complexity and procedural risks associated with pulmonary intervention," according to a press release.
Organ-transport system maker TransMedics notched a U.S. 1st in accommodating a "breathing lung" transplant at Ronald Reagan UCLA Medical center.
Using the same technology that made possible the "heart in a box" experiment, in which a donor heart was delivered warm and beating to a recipient rather than frozen in an ice cooler, doctors implanted a 57-year-old man with a functioning and "breathing" lung delivered in TransMedics’ Organ Care System.
Children’s Hospital of the King’s Daughters, a research center for chest-wall deformities and a training site for surgeons, performed 2 non-surgical vacuum procedures to correct a common chest deformity called pectus excavatum, also known as sunken chest syndrome.
The vacuum bell device, uses sustained pressure similar to those used in body shops to pop out dents, marked its 1st human use of a non-surgical pectus device, according to a press release.
Most startup medical device companies raise 10s of millions to research and develop their products before they even get to the commercial stage. But for Sanovas and co-founder Larry Gerrans, the 12-year journey to that point required a scant $9 million – all raised from the pulmonary device firm’s founders, friends and family, Gerrans told MassDevice.com last month.
The device has not been cleared for use in the U.S., but Medtronic plans to submit an application to the FDA, according to a press release.
Lung treatment company Pulmonx won FDA approval to begin pivotal clinical trials of its Zephyr Endobronchial Valve in treating patients with emphysema.
The minimally invasive Zephyr device is a one-way bronchial valve designed to reduce volume in diseased areas of the lungs, allowing healthier areas to work better. It’s implanted bronchoscopically and can be removed later if necessary, according to a press release.